CRISPR Therapeutics AG

-4.82 (-4.00%)
4:29:30 PM EDT: $115.28 -0.28 (-0.24%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)8.40B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.4 Million
Adjusted EPS-$1.49
See more estimates
10-Day MA$119.24
50-Day MA$135.97
200-Day MA$117.71
See more pivots

CRISPR Therapeutics AG Stock, NASDAQ:CRSP

Baarerstrasse 14, Zug, Zug 6300
Phone: +41.41.561.32.77
Number of Employees: 410


CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.